A study published in The BMJ this week shows how most new cancer drugs are failing to deliver any clinically meaningful benefit. It’s time for Europe to raise the evidence bar before market approval, finds Deborah Cohen
No takes yet. Share an insight, caveat, or question.
Deborah Cohen (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: